US 11,926,613 B2
Kinase inhibitors for the treatment of central and peripheral nervous system disorders
Hassan Al-Ali, Miami, FL (US); Vance Lemmon, Miami, FL (US); and John Bixby, Miami, FL (US)
Assigned to UNIVERSITY OF MIAMI, Miami, FL (US)
Appl. No. 16/760,365
Filed by UNIVERSITY OF MIAMI, Miami, FL (US)
PCT Filed Oct. 31, 2018, PCT No. PCT/US2018/058411
§ 371(c)(1), (2) Date Apr. 29, 2020,
PCT Pub. No. WO2019/089729, PCT Pub. Date May 9, 2019.
Claims priority of provisional application 62/579,368, filed on Oct. 31, 2017.
Prior Publication US 2021/0163444 A1, Jun. 3, 2021
Int. Cl. C07D 401/12 (2006.01); A61P 25/28 (2006.01); C07D 213/81 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 471/04 (2006.01)
CPC C07D 401/12 (2013.01) [A61P 25/28 (2018.01); C07D 213/81 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 471/04 (2013.01)] 15 Claims
 
1. A compound, or pharmaceutically acceptable salt thereof, having a structure of Formula (1):

OG Complex Work Unit Chemistry
wherein
ring A is an unsubstituted or substituted 5-6-membered monocyclic heteroaryl ring or a 8-11-membered bicyclic heteroaryl ring having 1, 2, or 3 nitrogen ring atoms;
L1 is null or C1-2alkylene;
X1 is —NH—, —CH2NH—, or —NHCH2—;
X2 is —NR2—;
X3 is —NR2—;
L2 is —C(O)—, —O—, —CH—, or —CH(OH)—;
R1 is H or halo;
each R2 is independently H or C1-3alkyl;
R3 is H, C1-3alky, C3-6cycloalkyl, aryl, C(O)C1-3alkyl, C(O)C3-6cycloalkyl, or C(O)aryl;
R4 is OH, halo, C1-4alkyl, or C1-4alkoxy; and
R5 is H.